Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN increased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 103.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 199,449 shares of the company's stock after purchasing an additional 101,179 shares during the period. Wells Fargo & Company MN owned approximately 0.40% of Prestige Consumer Healthcare worth $15,575,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. HighTower Advisors LLC increased its holdings in Prestige Consumer Healthcare by 4.9% in the third quarter. HighTower Advisors LLC now owns 16,708 shares of the company's stock valued at $1,215,000 after buying an additional 774 shares in the last quarter. Stifel Financial Corp raised its holdings in Prestige Consumer Healthcare by 13.7% during the third quarter. Stifel Financial Corp now owns 19,299 shares of the company's stock worth $1,391,000 after purchasing an additional 2,322 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Prestige Consumer Healthcare during the third quarter worth $6,342,000. Jane Street Group LLC grew its holdings in Prestige Consumer Healthcare by 28.3% in the third quarter. Jane Street Group LLC now owns 65,373 shares of the company's stock valued at $4,713,000 after purchasing an additional 14,434 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Prestige Consumer Healthcare in the third quarter valued at $264,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Up 0.4 %

Shares of PBH stock traded up $0.30 during trading hours on Friday, hitting $80.10. 292,350 shares of the company were exchanged, compared to its average volume of 286,084. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The firm has a fifty day moving average of $84.16 and a 200 day moving average of $80.16. The firm has a market cap of $3.97 billion, a PE ratio of 18.76, a PEG ratio of 2.69 and a beta of 0.47. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. The trade was a 8.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on PBH. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. StockNews.com cut shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Tuesday, April 8th. Canaccord Genuity Group upped their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Oppenheimer raised their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada increased their price objective on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research note on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.